| Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer V Noronha, VM Patil, A Joshi, N Menon, A Chougule, A Mahajan, A Janu, ... Journal of Clinical Oncology 38 (2), 124-136, 2020 | 359 | 2020 |
| Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma VM Patil, V Noronha, A Joshi, AB Choughule, A Bhattacharjee, R Kumar, ... ESMO open 2 (1), e000168, 2017 | 67 | 2017 |
| Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment V Noronha, A Choughule, VM Patil, A Joshi, R Kumar, DSJ Philip, ... OncoTargets and therapy 10, 2903, 2017 | 43 | 2017 |
| Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer … V Noronha, A Joshi, VM Patil, A Chougule, A Mahajan, A Janu, ... Journal of Clinical Oncology 37 (15_suppl), 9001-9001, 2019 | 38 | 2019 |
| Reasons for initiation of areca nut and related products in patients with oral submucous fibrosis within an endemic area in Gujarat, India CB More, NR Rao, S More, NW Johnson Substance Use & Misuse 55 (9), 1413-1421, 2020 | 26 | 2020 |
| Repeat biopsy in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer: Feasibility, limitations, and clinical utility in Indian patients S Zanwar, V Noronha, A Joshi, VM Patil, A Chougule, R Kumar, S More, ... Indian Journal of Cancer 54 (1), 280, 2017 | 13 | 2017 |
| Phase III randomized trial comparing intravenous to oral iron in patients with cancer‐related iron deficiency anemia not on erythropoiesis stimulating agents V Noronha, A Joshi, VM Patil, SD Banavali, S Gupta, PM Parikh, ... Asia‐Pacific Journal of Clinical Oncology 14 (2), e129-e137, 2018 | 10 | 2018 |
| Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC V Behel, A Chougule, V Noronha, VM Patil, N Menon, A Singh, ... Clinical Lung Cancer, 2022 | 8 | 2022 |
| Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study A Joshi, S Kate, V Noronha, V Patil, V Trivedi, S Goud, S More, S Bhairva, ... ecancermedicalscience 12, 2018 | 7 | 2018 |
| Impact of COVID-19 on oncology clinical trials: A “novel “challenge V Mathrudev, S Goud, S More, S Jain Cancer Research, Statistics, and Treatment 3 (5), 133, 2020 | 6 | 2020 |
| Phase III non-inferiority study evaluating efficacy and safety of low dose gemcitabine compared to standard dose gemcitabine with platinum in advanced squamous lung cancer V Patil, V Noronha, A Joshi, A Chougule, S Kannan, A Bhattacharjee, ... EClinicalMedicine 9, 19-25, 2019 | 6 | 2019 |
| P3. 02b-094 Rebiopsy Post Progression in EGFR Mutated Lung Cancer: Topic: EGFR RES A Chandrasekharan, V Patil, V Norohna, A Joshi, A Choughale, K Rajeev, ... Journal of Thoracic Oncology 12 (1), S1248-S1249, 2017 | 5 | 2017 |
| Epidermal growth factor receptor positive lung cancer: The nontrial scenario V Noronha, VM Patil, A Joshi, N Tandon, V Sharma, A Ramaswamy, ... Indian Journal of Cancer 54 (1), 132, 2017 | 5 | 2017 |
| Oral metronomic chemotherapy after definitive chemoradiation in esophageal squamous cell carcinoma: a randomized clinical trial V Noronha, VM Patil, NS Menon, A Joshi, S Goud, S More, S Kannan, ... Esophagus, 1-13, 2022 | 4 | 2022 |
| Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small … V Patil, A Joshi, V Noronha, V Agarwala, A Chougule, S Kanan, ... Oncotarget 10 (59), 6297, 2019 | 3 | 2019 |
| Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation? A Joshi, V Patil, V Noronha, A Chougule, A Bhattacharjee, R Kumar, ... Lung India: Official Organ of Indian Chest Society 35 (1), 27, 2018 | 3 | 2018 |
| Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation? A Joshi, V Noronha, VM Patil, A Chougule, A Bhattacharjee, R Kumar, ... Chemotherapy Research and Practice 2017, 2017 | 3 | 2017 |
| Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy V Noronha, V Patil, A Joshi, A Chougule, A Bhattacharjee, R Kumar, ... ecancermedicalscience 11, 2017 | 3 | 2017 |
| Oral leukoplakia: An overview with evidence based management C More, R Peter, K Shilu, S More International Journal of Oral and Maxillofacial Diseases, 2016 | 3 | 2016 |
| Prevalence and outcomes of frailty in older patients with cancer: A prospective study from geriatric oncology clinic. AR Rao, A Ramaswamy, S Kumar, S Gattani, R Dhekale, J Krishnamurthy, ... Journal of Clinical Oncology 40 (16_suppl), e24011-e24011, 2022 | 2 | 2022 |
